cellect biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration. achieving higher selectivity, greater specificity and decreased toxicity, cellect envisions its products becoming an integral and essential part of bone marrow transplantation (bmt), as well as integrated into many aspects of regenerative medicine.
Company profile
Ticker
QNRX
Exchange
Website
CEO
Shai Yarkoni
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cellect Biomed Ltd., Cellect Biotechnology Ltd.
SEC CIK
QNRX stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
9 Apr 24
EFFECT
Notice of effectiveness
4 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Apr 24
POS AM
Prospectus update (post-effective amendment)
29 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
13 Mar 24
424B3
Prospectus supplement
8 Mar 24
424B3
Prospectus supplement
8 Mar 24
8-K
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
8 Mar 24
424B4
Prospectus supplement with pricing info
6 Mar 24
Transcripts
QNRX
Earnings call transcript
2023 Q4
14 Mar 24
QNRX
Earnings call transcript
2023 Q3
9 Nov 23
QNRX
Earnings call transcript
2023 Q2
3 Aug 23
QNRX
Earnings call transcript
2023 Q1
9 May 23
QNRX
Earnings call transcript
2022 Q4
9 Mar 23
QNRX
Earnings call transcript
2022 Q3
10 Nov 22
QNRX
Earnings call transcript
2022 Q2
18 Aug 22
Latest ownership filings
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4
MICHAEL T SEMBER
30 Oct 23
4
Gordon Dunn
30 Oct 23
4
Michael Myers
30 Oct 23
4
Anthony James Culverwell
30 Oct 23
4
Joseph Patrick Cooper
30 Oct 23
4
Natalie Ee Mun Leong
30 Oct 23
4
Denise P. Carter
30 Oct 23
4
DENNIS LANGER
30 Oct 23
3
MICHAEL T SEMBER
7 Mar 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.16 mm | 3.16 mm | 3.16 mm | 3.16 mm | 3.16 mm | 3.16 mm |
Cash burn (monthly) | 531.90 k | 359.95 k | (no burn) | (no burn) | (no burn) | 136.71 k |
Cash used (since last report) | 3.55 mm | 2.40 mm | n/a | n/a | n/a | 912.76 k |
Cash remaining | -387.84 k | 760.23 k | n/a | n/a | n/a | 2.25 mm |
Runway (months of cash) | -0.7 | 2.1 | n/a | n/a | n/a | 16.5 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 3.66 mm |
Total shares | 1.27 bn |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 1.27 bn | $0.00 |
Lind Global Fund II | 990.00 k | $465.00 k |
VIRT Virtu Financial | 147.91 k | $70.00 k |
Renaissance Technologies | 13.90 k | $7.00 k |
UBS UBS Group AG - Registered Shares | 6.56 k | $3.12 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Oct 23 | Denise P. Carter | Share Option American Depositary Share | Grant | Acquire A | No | No | 5.75 | 80,966 | 465.55 k | 80,966 |
26 Oct 23 | Dennis Langer | Share Option American Depositary Share | Grant | Acquire A | No | No | 5.75 | 7,652 | 44.00 k | 7,652 |
26 Oct 23 | Natalie Ee Mun Leong | Share Option American Depositary Share | Grant | Acquire A | No | No | 5.75 | 7,652 | 44.00 k | 7,652 |
26 Oct 23 | Joseph Patrick Cooper | Share Option American Depositary Share | Grant | Acquire A | No | No | 5.75 | 7,652 | 44.00 k | 7,652 |
26 Oct 23 | Anthony James Culverwell | Share Option American Depositary Share | Grant | Acquire A | No | No | 5.75 | 7,652 | 44.00 k | 7,652 |
News
Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know
15 Mar 24
Maxim Group Maintains Buy on Quoin Pharmaceuticals, Lowers Price Target to $4
15 Mar 24
Quoin Pharmaceuticals: Q4 Earnings Insights
13 Mar 24
Quoin Pharmaceuticals Q4 2023 GAAP EPS $(2.08) Beats $(2.31) Estimate
13 Mar 24
Earnings Scheduled For March 13, 2024
13 Mar 24
Press releases
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
7 Mar 24
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
4 Mar 24
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
14 Feb 24